LINC02017

Across TCGA pan-cancer cohorts, LINC02017 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated LINC02017 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LINC02017 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02017 expression acts as an unfavorable survival marker, although some lineages such as ESCA and COAD show a favorable association.

STAD, LUSC, and CHOL are the cancer types where LINC02017 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	II,III,IV	0.491	0.750	.002	78	view →
LUSC	DFS	Tertile	III,IV	0.223	0.692	<.001	54	view →
CHOL	DFS	Tertile	All	0.041	0.522	<.001	45	view →
GBM	OS	Tertile	All	0.265	0.442	.001	45	view →
ACC	OS	Tertile	All	0.468	0.862	<.001	42	view →
ESCA	DFS	Tertile	III,IV	0.729	0.260	.006	33	view →
SKCM	DFS	Tertile	II,III,IV	0.374	0.580	.008	30	view →
PAAD	OS	Tertile	II,III,IV	0.424	0.653	.040	27	view →
COAD	OS	Tertile	IV	0.917	0.481	.027	27	view →
THCA	OS	Tertile	III,IV	0.738	0.985	.002	24	view →
PCPG	DFS	Tertile	All	0.586	0.866	.007	24	view →
LGG	OS	Median	All	0.949	0.860	<.001	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

LINC02017–STAD (OS)

Open the STAD breakdown →